Abstract
Introduction
In the drug discovery process, drug permeation across the blood-brain barrier (BBB) is fundamental for neuropharmaceuticals to reach their site of action within the central nervous system (CNS). This BBB consists of highly specialised microvascular endothelial cells together with pericytes, astrocytes, microglia, neurons and basement membrane 1 . The capillary endothelial cells are connected by proteins (occludin, claudins and junctional adhesion molecules) forming tight junctions (TJs), which seal the intercellular space, thereby restricting the permeability for the CNS-active substances 2, 3 . In addition, these cells contain numerous active membrane transporters to regulate transcellular transport of drug-like molecules and their metabolites between the blood-brain interface.
Over 98% of all known therapeutics are unable to penetrate the BBB due to their molecular properties and physicochemical factors, including hydrophilicity, hydrophobicity, polar surface area, molecular size and charge ( Figure 1 ). On the contrary, the permeation of the CNS-inactive compounds would generate various undesired side effects. Receptormediated and non-specific adsorption-mediated transcytosis can also contribute to the translocation of peptides, antibodies and lipoproteins across the BBB 4 . To minimise this risk, the healthy BBB itself imposes a highly efficient impediment for most of the clinically administered neuropharmaceuticals. On the other hand, the BBB dysfunction is highly implicated in auto-immune, neuropathological processes (Alzheimer and Parkinson's diseases), neuroinfections (meningitis and encephalitis), haemorrhagic and ischemic stroke and traumatic brain injury [5] [6] [7] . In this regard, the assessment of the BBB permeation for drug candidates at physiological and pathological conditions would be a primary concern for rational drug design and development through various in silico, in vitro and in vivo methods.
The goal of this review is to describe the state-of-the-art techniques and methods that have been used so far in pharmaceutical research to evaluate the BBB function and assess the ability of drug-like molecules to permeate the BBB.
We performed a literature search and study selection by seeking published biomedical research papers in PubMed. The criteria for search were as follows:
• article type: review, research article • publication date: various • species: mammals • language: English • key words: blood-brain barrier, in silico, in vitro, in vivo methods, drug-like compounds, rational drug design
We also used monographs dedicated to the BBB research and drug design strategies to bring readers the state-of the-art information in regard to describing issues.
Discussion
The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) Aside from the Lipinski's rule of thumb, the other methods were also elaborated to predict the ability of substances to permeate the BBB successfully and exert their pharmacological potential. Among them are various quantitative structure-activity relationship (QSAR) regression models based on the BBB partitioning values, such as logBB, taken from experimental data for various druglike molecules 9 . The logBB parameter is defined as the logarithm value of steady-state brain to blood (plasma) concentration ratio for a drug of interest according to following equation: logBB = log (c brain /c blood )
In molecular descriptor-based analysis, the predicted logBB parameter was mainly derived from the notion of molecular polar surface area descriptor and octanol-water partition coefficient (logP) to assess compound hydrophobicity and Hbonding capacity (desolvation rate). These two last descriptors were vigorously discussed throughout the literature 10, 11 . For instance, they were implemented continuously in the QSAR regression models through many mathematical formulas, such as Clark and Rishton equations 12, 13 :
On the other hand, the molecular docking-based methods have been successfully used to determine the P-glycoprotein substrates or inhibitors dealing with the phenomenon of active multidrug efflux by P-gp in the brain 14, 15 . Despite its relative precision, this approach depends on the accurate crystallographic three-dimensional models of the protein structure and implements laborious ligandreceptor preparations and computationally slow genetic algorithms 16, 17 . Therefore, this approach is particularly valuable when used in combination with previously described methods (HTS) is a method of choice to filter and determine the CNS-active drug/ hit/lead-like compounds either by the descriptor-or by the molecular docking-based strategy ( Figure 2) .
As for the descriptor-based HTS, the great assessment in this direction was done by Lipinski and co-authors, characterised in a literature as the Rule of Five 8 . Despite the fact that the Rule of Five was widely adopted by both pharmaceutical industry and academia for its robustness (few false-negatives) and fast calculation speed, there were disadvantages of the method. Among those were lots of false-positive outcomes due to simple summation of molecular properties (molecular weight, sum of nitrogen and oxygen atoms, etc.) without considering the BBB transport mechanisms, such as multidrug P-glycoprotein (P-gp) transporter efflux and strong reliance on experimentally determined datasets. in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies.
In silico methods
The in silico prediction methods have acquired popularity in the last few decades in the BBB research because of their speed, flexibility, low cost and less time-consuming efforts in comparison to in vitro and in vivo approaches. Therefore, a new strategy has evolved based on the computational simulation and prediction of compound interaction with the BBB interface to expedite and improve rational drug design and discovery at its early stage.
To screen the virtual libraries that encompass up to hundreds of thousands and even millions of drug-like molecules, numerous procedures were devised based on their molecular descriptors and fingerprints. A standard high-throughput screening . In addition, it is selectively permeable to molecules 19 and displays functional mechanisms of active extrusion 20 or active transport 21, 22 . Cells of both cerebral and noncerebral origin are used as in vitro models of the BBB. Isolation of brain capillaries and culture of brain capillary endothelial cells (BCECs) are both employed. However, due to the limitations of currently available immortalised BCEC lines since some of them have insufficient barrier properties, the cells of non-cerebral origin might be also used to build a barrier. Isolated brain capillaries are used for BBB transport studies [23] [24] [25] . Freshly isolated capillaries directly reflect the situation at the luminal side of brain capillaries. In fact, they reflect the in vivo situation very well. However, they are not well suited for the BBB permeation studies since the luminal surface of the microvessels is difficult to access.
Primary BCECs also mimic the in vivo situation that makes them favourable in an in vitro model for BBB research. They provide a close phenotypic resemblance to in vivo BBB cells. However, it takes time to isolate, seed and incubate BCECs. Moreover, it is difficult to reproduce the same phenotypic and permeability properties for every experiment when using this cell type. Primary or low-passage porcine BCECs were the 'pioneer' cells used as an in vitro permeability model 26 .
In order to overcome the problems concerning reproducibility of primary BCECs, immortalised are very important. Systems that can be used for HTS are favoured. Moreover, methods that allow for direct access to the brain endothelium with no interference from other brain structures are preferred. In vitro models allow for this which are the more common choice for such to exclude the role of active transport as a result of drug-P-gp interaction upon the BBB permeation of drug-like chemical compounds.
In vitro methods
In CNS research, BBB permeability properties of drug-like candidates 
In vivo methods
While in silico and in vitro methods have many significant advantages to perform substantial screening of drug-like chemical compounds, the BBB permeation analysis should not rely solely on them. Therefore, in vivo techniques made it possible to correlate the data produced by previous methods, determine and confirm the final results and clarify the BBB molecular mechanisms considering the complexity of living organisms 40 . There are various in vivo methods (some of which are not in the scope of this review) that have been utilised to evaluate the BBB permeation mechanism, including the highperformance liquid chromatography (HPLC) analysis of brain homogenates, in situ brain perfusion and intracerebral microdialysis ( Figure 5 ). Each of these invasive techniques is suitable to experimentally determine the logBB and/or logPS (logarithm of permeability-surface area product) values under appropriate physiological and pathological conditions. The HPLC analysis of mouse or rat brain homogenates is a crude method of choice; it starts with a homogenate preparation by ultrasonication in Dulbecco's phosphate-buffered saline (PBS) or other matrices following high-speed centrifugation to produce a clear supernatant for further determination of drug concentration by HPLC. The major disadvantage
The first in vitro BBB filter model was introduced in the 1980s using bovine brain endothelial cells 35 . The insert was composed of nylon mesh and polycarbonate tubing. A variety of chambers and inserts from different materials and pore sizes later became commercially available.
To compensate for the aforementioned lack in shear stress as affecting endothelial barrier function, dynamic BBB models were established 36 . In these models, hollow fibres that mimic capillaries and allow co-culture of other cell types were used (Figure 4 ). Bovine aortic endothelial cells co-cultured with glial cells were the first BBB model to adopt this method 37 . More recently, immortalised porcine brain endothelial cells co-cultured with glial cells 38 were used. The human cerebral microvascular endothelial cell line (hCMEC/D3) co-cultured with astrocytes grown in the lumen of hollow microporous fibres and exposed to a physiological pulsatile flow was also recently developed as a dynamic BBB model 39 . This method demonstrated that hCMEC/D3 cells cultured under pulsatile flow conditions have maintained in vitro physiological permeability barrier properties of BCECs are established for in vitro BBB permeation studies. For instance, the murine cerebrovascular endothelial cell line (cEND) was generated and its barrier properties were enhanced by glucocorticoid treatment [27] [28] [29] . Improvement of barrier properties has also been reported in porcine cerebral capillary endothelial cells 26 , rat BCECs 30 and human dermal microvascular endothelial cell line (hDMEC/D3) 31 . Meanwhile, BCECs can also be co-cultured with astrocytes 32 , C6 glioma cells 33 or pericytes 34 to improve barrier properties. These cells can be grown either with or without contact with BCECs in a Transwell culture system. Transwell models have been developed to study BBB permeation. Most permeability experiments employ this method. It can be a monodimensional system, wherein which only BCECs are grown on a microporous membrane or a two-dimensional system wherein the BCECs are co-cultured with other cells (Figure 3A-C) .
However, all these systems lack the experimental replication of intraluminal blood cells together with bloodstream flow that imparts shear stress as it is occurring in vivo.
A B C . The most frequently used animal for brain perfusions is the rat, although this method has also been successfully applied in dog, guinea pig and mice studies [44] [45] [46] . Although this method takes longer to perform compared to carotid artery single injection, it is more sensitive due to the prolonged duration. It also allows the estimation of PS product for those compounds that penetrate easily or very poorly. In the course of in situ brain perfusion, the compound being tested is not systemically exposed; therefore it avoids metabolism in the liver. In addition, many factors of the perfusate such as concentration and constituents can be controlled and varied 47 . A serious disadvantage of this method, however, is the large number of animals needed for complete kinetic analysis. In addition, radiolabelled or reference compounds are required for analysis.
Intracerebral microdialysis is a valuable tool in pharmaceutical research that is used to perform a direct sampling of cerebral interstitial fluid via establishing a dialysis catheter with semipermeable membrane into the brain 48 . Therefore, the molecule of interest from the brain will where t is the duration of the perfusion period (min) and V D or V 0 is the brain volume of distribution for the test and reference compound respectively and calculated as the brain/ perfusate concentration at time t 43 . In situ brain perfusion does not alter the BBB integrity and can be used to accurately determine permeability coefficients for solutes ranging from of this approach is that the residual capillary blood in the brain might influence the results and, therefore, should be eliminated via brain reperfusion with PBS before surgery or in situ brain perfusion 41 . The other hurdles and difficulties in HPLC measurements include a high lipid and protein composition presented in the brain, which bind to a chemical entity (protein/lipid-bound drug fraction) and sediment along with it.
The in situ perfusion technique was first developed by Takasato et al. 42 . In this method, the right cerebral hemisphere of the rat is perfused in situ (in place), with the reference and test compounds retrograde via the external into the internal carotid artery in anaesthetised rats.
After perfusion, the animals are decapitated and the brain is analysed for reference and test compounds to quantify the logPS coefficient, which is a calculation method based on the rate of brain penetration for analysed chemical entity. The logPS parameter is calculated as follows: 
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traverse this membrane according to its concentration gradient (from high to low) that makes it possible to analyse within the collected fluid (microdialysate) 49, 50 . This technique allows the possibility to monitor the drug concentration in the brain over time within the same animal and probe different brain areas as presumable drug targets. The potential drawbacks may include chronic BBB inflammation and disruption caused by this invasive procedure followed by increased BBB leakage and plasma protein extravasation 51 . Despite these shortcomings, this method of choice is still the only technique that provides information about the local concentration of unbound fraction of drug-like substances at any given time in freely moving animals.
Conclusion
Diverse in silico, in vitro and in vivo methods for the estimation of druglike molecules transferred across the BBB have been devised for pharmaceutical research by industry and academia in the last few decades. Presently, all these methods have their intrinsic advantages and limitations emphasised in this current review. The more reliable in vivo methodologies are still not applicable for HTS of huge molecular databases generated by combinatorial chemistry manipulations. For that reason, additional in silico and in vitro techniques were widely adopted by bioscientists to expedite a compound selection process, fully assess the brain uptake for chemical entities and better understand the complex mechanisms underlying BBB transport. Therefore, the use of a combined screening process, including in silico, in vitro and in vivo methods, may achieve greater reliabilities in predicting and measuring the BBB permeation potential of promising drug candidates in humans.
